References
- ZangerUMSchwabMCytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variationPharmacol Ther2013138110314123333322
- De MoraisSMWilkinsonGRBlaisdellJMeyerUANakamuraKGoldsteinJAIdentification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in JapaneseMol Pharmacol19944645945987969038
- De MoraisSMWilkinsonGRBlaisdellJNakamuraKMeyerUAGoldsteinJAThe major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humansJ Biol Chem19942692215419154228195181
- SimSRisingerCDahlMLCommon novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsClin Pharmacol Ther200679110311316413245
- BaldwinRMOhlssonSPedersenRSIncreased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteersBr J Clin Pharmacol200865576777418294333
- SwenJJNijenhuisMde BoerAPharmacogenetics: from bench to byte-an update of guidelinesClin Pharmacol Ther201189566267321412232
- BalianJDSukhovaNHarrisJWThe hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population studyClin Pharmacol Ther19955766626697781266
- AnderssonTRegårdhCGLouYCZhangYDahlMLBertilssonLPolymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjectsPharmacogenetics19922125311302040
- OhnishiAMurakamiSAkizukiSMochizukiJEchizenHTakagiIIn vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver diseaseJ Clin Pharmacol200545111221122916239354
- ScottSASangkuhlKSteinCMClinical Pharmacogenetics Implementation ConsortiumClinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 updateClin Pharmacol Ther201394331732323698643
- CrettolSDéglonJJBessonJMethadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatmentClin Pharmacol Ther200578659360416338275
- YamadaHDahlMLLannfeltLViitanenMWinbladBSjöqvistFCYP2D6 and CYP2C19 genotypes in an elderly Swedish populationEur J Clin Pharmacol19985464794819776439
- ManMFarmenMDumaualCGenetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and AfricansJ Clin Pharmacol201050892994020173083
- SánchezMBHerranzJLLenoCGenetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsySeizure20101929310120064729
- GaikovitchEACascorbiIMrozikiewiczPMPolymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian populationEur J Clin Pharmacol200359430331212879168
- PayanMRouiniMRTajikNGhahremaniMHTahvilianRHydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian populationDaru20142218125498969
- NoubaraniMKobarfardFMotevalianMKeyhanfarFVariation in omeprazole pharmacokinetics in a random Iranian population: a pilot studyBiopharm Drug Dispos201233632433122890488
- TanakaSUchidaSInuiNTakeuchiKWatanabeHNamikiNSimultaneous LC-MS/MS analysis of the plasma concentrations of a cocktail of 5 cytochrome P450 substrate drugs and their metabolitesBiol Pharm Bull2014371182524389476
- De AndrésFTeránSBoveraMFariñasHTeránELLerenaAMultiplex phenotyping for systems medicine: a one-point optimized practical sampling strategy for simultaneous estimation of CYP1A2, CYP2C9, CYP2C19, and CYP2D6 activities using a cocktail approachOMICS2016202889626600202
- PurisEPasanenMGyntherMA liquid chromatography-tandem mass spectrometry analysis of nine cytochrome P450 probe drugs and their corresponding metabolites in human serum and urineAnal Bioanal Chem2017409125126827734142
- GumusEKaracaOBabaogluMOEvaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhoodEur J Clin Pharmacol201268562963622076562
- NiiokaTUnoTSugimotoKSugawaraKHayakariMTateishiTEstimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administrationEur J Clin Pharmacol200763111031103817701405
- RostKLBrösickeHBrockmöllerJSchefflerMHelgeHRootsIIncrease of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoinClin Pharmacol Ther19925221701801505152
- ParkinsonAHurwitzAOmeprazole and the induction of human cytochrome P-450: a response to concerns about potential adverse effectsGastroenterology1991100411571164